Tegaserod in constipation associated with Parkinson disease

John Christopher Morgan, Kapil Dev Sethi

Research output: Contribution to journalArticlepeer-review

30 Scopus citations


Impaired gastrointestinal motility and constipation are common problems in Parkinson disease (PD). Many patients with PD continue to experience constipation, despite multiple interventions (dietary modification, bulk-forming agents, stool softeners, and laxatives). Tegaserod is a 5-hydroxytryptamine type 4 agonist that stimulates gastrointestinal motility and is approved for the treatment of chronic idiopathic constipation. We report our experience with tegaserod in 5 patients with PD-associated constipation. Tegaserod was well tolerated and improved both bowel movement frequency and stool consistency in most of our patients. Further trials with tegaserod are warranted in PD-associated constipation.

Original languageEnglish (US)
Pages (from-to)52-54
Number of pages3
JournalClinical Neuropharmacology
Issue number1
StatePublished - Jan 1 2007


  • 5-HT agonist
  • Constipation
  • Parkinson disease
  • Tegaserod

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Neurology
  • Pharmacology (medical)


Dive into the research topics of 'Tegaserod in constipation associated with Parkinson disease'. Together they form a unique fingerprint.

Cite this